menu
    • menu
    [{"orgOrder":0,"company":"Salus Pharmaceuticals","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Aztreonam","moa":"Bacterial penicillin-binding protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Salus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Salus Pharmaceuticals \/ Salus Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Salus Pharmaceuticals \/ Salus Pharmaceuticals"},{"orgOrder":0,"company":"Salus Pharmaceuticals","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salus Pharmaceuticals \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Salus Pharmaceuticals \/ AFT Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Salus Pharmaceuticals

    Menu

    Salus Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Salus Pharmaceuticals

                            India arrow
                            CPhI India
                            Not Confirmed

                            Salus Pharmaceuticals

                            India arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Ibuprofen

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : AFT Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries

                            Details : Maxigesic (paracetamol) IV is a novel, dual mode-of-action, non-opioid pain treatment delivered through intravenous (IV) infusion for use post-operatively in hospitals or when patients cannot take medicine orally.

                            Product Name : Maxigesic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Paracetamol,Ibuprofen

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : AFT Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Salus Pharmaceuticals

                            India arrow
                            CPhI India
                            Not Confirmed

                            Salus Pharmaceuticals

                            India arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aztreonam

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

                            Details : Aztreonam is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 26, 2010

                            Lead Product(s) : Aztreonam

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth